Eli Lilly and Company $LLY Shares Bought by Cambria Investment Management L.P.

Cambria Investment Management L.P. increased its holdings in Eli Lilly and Company (NYSE:LLY) by 255.2% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,428 shares of the company’s stock after purchasing an additional 1,026 shares during the quarter. Cambria Investment Management L.P.’s holdings in Eli Lilly and Company were worth $1,090,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in LLY. 10Elms LLP increased its holdings in shares of Eli Lilly and Company by 33.3% in the third quarter. 10Elms LLP now owns 40 shares of the company’s stock valued at $31,000 after buying an additional 10 shares in the last quarter. Bridgewater Advisors Inc. boosted its stake in shares of Eli Lilly and Company by 0.3% during the 3rd quarter. Bridgewater Advisors Inc. now owns 3,955 shares of the company’s stock worth $3,018,000 after acquiring an additional 11 shares in the last quarter. Manske Wealth Management boosted its stake in shares of Eli Lilly and Company by 2.5% during the 3rd quarter. Manske Wealth Management now owns 448 shares of the company’s stock worth $342,000 after acquiring an additional 11 shares in the last quarter. Guardian Partners Inc. grew its holdings in shares of Eli Lilly and Company by 0.3% in the 3rd quarter. Guardian Partners Inc. now owns 4,000 shares of the company’s stock worth $3,302,000 after acquiring an additional 12 shares during the last quarter. Finally, FSA Wealth Management LLC grew its holdings in shares of Eli Lilly and Company by 4.0% in the 3rd quarter. FSA Wealth Management LLC now owns 309 shares of the company’s stock worth $236,000 after acquiring an additional 12 shares during the last quarter. 82.53% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several brokerages have recently commented on LLY. Jefferies Financial Group set a $1,300.00 target price on Eli Lilly and Company and gave the company a “buy” rating in a report on Friday, March 13th. Guggenheim lifted their price target on Eli Lilly and Company from $1,161.00 to $1,168.00 and gave the stock a “buy” rating in a research note on Thursday, February 26th. Royal Bank Of Canada initiated coverage on Eli Lilly and Company in a report on Tuesday, February 24th. They set an “outperform” rating and a $1,250.00 price objective on the stock. UBS Group reaffirmed a “buy” rating on shares of Eli Lilly and Company in a research note on Wednesday. Finally, National Bank Financial set a $1,286.00 target price on shares of Eli Lilly and Company in a report on Monday, December 1st. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $1,221.44.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Phase 3 “TRANSCEND‑T2D‑1” topline: retatrutide (triple agonist) produced big A1C drops (≈1.7–2.0%) and ~16.8% weight loss at 40 weeks, with no plateau — a potential blockbuster next‑generation obesity/diabetes drug that could extend Lilly’s leadership and revenue runway. Lilly PR Newswire: Retatrutide Results
• Positive Sentiment: Pipeline breadth: Lilly launched a master IBD study and is advancing mirikizumab delivery and oral ulcerative colitis candidates — diversification beyond GLP‑1s that supports multiple future revenue streams. TipRanks: Master IBD Study
• Positive Sentiment: Capacity & manufacturing investment: Lilly is spending heavily to expand and modernize production (major plant plans and ~$1.8B+/upcoming $3.5B campus reports), reducing future supply risk for high-demand obesity/diabetes drugs. IBJ: Lilly Manufacturing Investment
• Neutral Sentiment: Additional coverage and patient data (Forbes/Benzinga/CNBC) reiterate strong weight‑loss and glycemic results for retatrutide — helpful for commercial narrative but largely a confirmation of the PR-driven catalyst already priced in by some investors. Forbes: Patient Results
• Neutral Sentiment: Reported insider/congressional buying is noted by media (visibility signal) but is not a reliable near‑term catalyst for price direction. MarketBeat: Congressional Trades
• Negative Sentiment: HSBC downgrade to “Reduce” (PT cut to ~$850) flagged persistent U.S. pricing pressure, rising competition and compounded tirzepatide risks — the downgrade has driven analyst-led selling and is the main immediate negative driver. Yahoo Finance: HSBC Downgrade
• Negative Sentiment: Competitive risk: Novo Nordisk won FDA clearance for a higher‑dose Wegovy (7.2 mg) with strong weight‑loss data and an April launch planned — intensifying head‑to‑head competition in the obesity market that could pressure pricing and share. Blockonomi: Novo Nordisk Higher Dose Wegovy

Eli Lilly and Company Trading Down 0.1%

NYSE:LLY opened at $916.94 on Friday. The company has a market capitalization of $866.34 billion, a P/E ratio of 39.95, a P/E/G ratio of 1.07 and a beta of 0.40. The stock’s 50 day moving average price is $1,026.34 and its 200 day moving average price is $954.98. The company has a debt-to-equity ratio of 1.54, a quick ratio of 1.19 and a current ratio of 1.58. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $1,133.95.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Wednesday, February 4th. The company reported $7.54 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $7.48 by $0.06. The firm had revenue of $19.29 billion during the quarter, compared to analysts’ expectations of $17.85 billion. Eli Lilly and Company had a net margin of 31.66% and a return on equity of 102.94%. The company’s revenue was up 42.6% compared to the same quarter last year. During the same period in the previous year, the company earned $5.32 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. On average, research analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.